Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development a
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, w...
Source: pharmiweb.com